Targeted drug delivery system to neural cells utilizes the nicotinic acetylcholine receptor

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Drug delivery to the brain is still a major challenge in the field of therapeutics, especially for large and hydrophilic compounds. In order to achieve drug delivery of therapeutic concentration in the central nervous system, the problematic blood brain barrier (BBB) must be overcome. This work presents the formulation of a targeted nanoparticle-based drug delivery system using a specific neural cell targeting ligand, rabies virus derived peptide (RDP). Characterization studies revealed that RDP could be conjugated to drug-loaded PLGA nanoparticles of average diameter 257.10 ± 22.39 nm and zeta potential of -5.51 ± 0.73 mV. In vitro studies showed that addition of RDP to nanoparticles enhanced drug accumulation in a neural cell line specifically as opposed to non-neural cell lines. It was revealed that this drug delivery system is reliant upon nicotinic acetylcholine receptor (nAChR) function for RDP-facilitated effects, supporting a cellular uptake mechanism of action. The specific neural cell targeting capabilities of RDP via the nAChR offers a non-toxic, non-invasive and promising approach to the delivery of therapeutics to the brain.
LanguageEnglish
Pages12-20
Number of pages8
JournalInternational Journal of Pharmaceutics
Volume525
Issue number1
Early online date12 Apr 2017
DOIs
Publication statusPublished - 15 Jun 2017

Fingerprint

Rabies virus
Nicotinic Receptors
Drug Delivery Systems
Peptides
Nanoparticles
Pharmaceutical Preparations
Cell Line
Brain
Blood-Brain Barrier
Therapeutics
Central Nervous System
Ligands

Keywords

  • Drug delivery system
  • rabies virus
  • targeted nanoparticles
  • neural
  • blood brain barrier (BBB)
  • nicotinic acetylcholine receptor

Cite this

@article{f8de2f4a28d2401387d80058236d0687,
title = "Targeted drug delivery system to neural cells utilizes the nicotinic acetylcholine receptor",
abstract = "Drug delivery to the brain is still a major challenge in the field of therapeutics, especially for large and hydrophilic compounds. In order to achieve drug delivery of therapeutic concentration in the central nervous system, the problematic blood brain barrier (BBB) must be overcome. This work presents the formulation of a targeted nanoparticle-based drug delivery system using a specific neural cell targeting ligand, rabies virus derived peptide (RDP). Characterization studies revealed that RDP could be conjugated to drug-loaded PLGA nanoparticles of average diameter 257.10 ± 22.39 nm and zeta potential of -5.51 ± 0.73 mV. In vitro studies showed that addition of RDP to nanoparticles enhanced drug accumulation in a neural cell line specifically as opposed to non-neural cell lines. It was revealed that this drug delivery system is reliant upon nicotinic acetylcholine receptor (nAChR) function for RDP-facilitated effects, supporting a cellular uptake mechanism of action. The specific neural cell targeting capabilities of RDP via the nAChR offers a non-toxic, non-invasive and promising approach to the delivery of therapeutics to the brain.",
keywords = "Drug delivery system, rabies virus, targeted nanoparticles, neural, blood brain barrier (BBB), nicotinic acetylcholine receptor",
author = "Rachel Huey and Barry O'Hagan and Paul McCarron and Susan Hawthorne",
year = "2017",
month = "6",
day = "15",
doi = "10.1016/j.ijpharm.2017.04.023",
language = "English",
volume = "525",
pages = "12--20",
journal = "International Journal of Pharmaceutics",
issn = "0378-5173",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Targeted drug delivery system to neural cells utilizes the nicotinic acetylcholine receptor

AU - Huey, Rachel

AU - O'Hagan, Barry

AU - McCarron, Paul

AU - Hawthorne, Susan

PY - 2017/6/15

Y1 - 2017/6/15

N2 - Drug delivery to the brain is still a major challenge in the field of therapeutics, especially for large and hydrophilic compounds. In order to achieve drug delivery of therapeutic concentration in the central nervous system, the problematic blood brain barrier (BBB) must be overcome. This work presents the formulation of a targeted nanoparticle-based drug delivery system using a specific neural cell targeting ligand, rabies virus derived peptide (RDP). Characterization studies revealed that RDP could be conjugated to drug-loaded PLGA nanoparticles of average diameter 257.10 ± 22.39 nm and zeta potential of -5.51 ± 0.73 mV. In vitro studies showed that addition of RDP to nanoparticles enhanced drug accumulation in a neural cell line specifically as opposed to non-neural cell lines. It was revealed that this drug delivery system is reliant upon nicotinic acetylcholine receptor (nAChR) function for RDP-facilitated effects, supporting a cellular uptake mechanism of action. The specific neural cell targeting capabilities of RDP via the nAChR offers a non-toxic, non-invasive and promising approach to the delivery of therapeutics to the brain.

AB - Drug delivery to the brain is still a major challenge in the field of therapeutics, especially for large and hydrophilic compounds. In order to achieve drug delivery of therapeutic concentration in the central nervous system, the problematic blood brain barrier (BBB) must be overcome. This work presents the formulation of a targeted nanoparticle-based drug delivery system using a specific neural cell targeting ligand, rabies virus derived peptide (RDP). Characterization studies revealed that RDP could be conjugated to drug-loaded PLGA nanoparticles of average diameter 257.10 ± 22.39 nm and zeta potential of -5.51 ± 0.73 mV. In vitro studies showed that addition of RDP to nanoparticles enhanced drug accumulation in a neural cell line specifically as opposed to non-neural cell lines. It was revealed that this drug delivery system is reliant upon nicotinic acetylcholine receptor (nAChR) function for RDP-facilitated effects, supporting a cellular uptake mechanism of action. The specific neural cell targeting capabilities of RDP via the nAChR offers a non-toxic, non-invasive and promising approach to the delivery of therapeutics to the brain.

KW - Drug delivery system

KW - rabies virus

KW - targeted nanoparticles

KW - neural

KW - blood brain barrier (BBB)

KW - nicotinic acetylcholine receptor

U2 - 10.1016/j.ijpharm.2017.04.023

DO - 10.1016/j.ijpharm.2017.04.023

M3 - Article

VL - 525

SP - 12

EP - 20

JO - International Journal of Pharmaceutics

T2 - International Journal of Pharmaceutics

JF - International Journal of Pharmaceutics

SN - 0378-5173

IS - 1

ER -